The Medicare Services Advisory Committee (MSAC) has recommended funding of emicizumab (Hemlibra) via the National Blood Authority for patients with moderate or severe haemophilia A without factor VIII inhibitors. However, MSAC said in its advice to the Minister for Health the application for funding “did not justify the expense of emicizumab for all patients, and ...
Emicizumab gets funding recommendation for haemophilia A
By Michael Woodhead
29 Jan 2020